The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are ...

The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s ...

The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s ...

Dimension, a young venture capital firm at the vanguard of biotechnology’s embrace of artificial intelligence, has closed its biggest fund to date. The firm on Tuesday announced it raised $800 million ...

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

Eli Lilly plans to acquire psychedelics specialist AtaiBeckley through a multibillion-dollar deal that shows big pharma’s growing endorsement of a once-dimissed, now rapidly emerging research field.

The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.

The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from ...

Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class ...

Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted ...